Summary:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis.
Qualified Participants Must:
• Demonstrated an inadequate response, loss of response, or intolerance to at least one of the following treatments including:
-oral aminosalicylates
-corticosteroids
-immunosuppressants
-biologic therapies
Qualified Participants May Receive:
Free Medication
Free Treatment
Compensation for time and travel